Format

Send to

Choose Destination
Mol Ther. 2014 Jan;22(1):69-80. doi: 10.1038/mt.2013.214. Epub 2013 Sep 12.

Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles.

Author information

1
Department of Chemistry and Biology, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA.
2
Department of Pathology, School of Medicine, Emory University, Atlanta, Georgia, USA.
3
1] Department of Chemistry and Biology, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia, USA [2] Veterans Affairs Medical Center, Decatur, Georgia, USA.

Abstract

Intestinal CD98 expression plays a crucial role in controlling homeostatic and innate immune responses in the gut. Modulation of CD98 expression in intestinal cells therefore represents a promising therapeutic strategy for the treatment and prevention of inflammatory intestinal diseases, such as inflammatory bowel disease. Here, the advantages of nanoparticles (NPs) are used, including their ability to easily pass through physiological barriers and evade phagocytosis, high loading concentration, rapid kinetics of mixing and resistance to degradation. Using physical chemistry characterizations techniques, CD98 siRNA/polyethyleneimine (PEI)-loaded NPs was characterized (diameter of ~480 nm and a zeta potential of -5.26 mV). Interestingly, CD98 siRNA can be electrostatically complexed by PEI and thus protected from RNase. In addition, CD98 siRNA/PEI-loaded NPs are nontoxic and biocompatible with intestinal cells. Oral administration of CD98/PEI-loaded NPs encapsulated in a hydrogel reduced CD98 expression in mouse colonic tissues and decreased dextran sodium sulfate-induced colitis in a mouse model. Finally, flow cytometry showed that CD98 was effectively downregulated in the intestinal epithelial cells and intestinal macrophages of treated mice. Finally, the results collectively demonstrated the therapeutic effect of "hierarchical nano-micro particles" with colon-homing capabilities and the ability to directly release "molecularly specific" CD98 siRNA in colonic cells, thereby decreasing colitis.

PMID:
24025751
PMCID:
PMC3978807
DOI:
10.1038/mt.2013.214
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center